Partially PEGylated PAMAM dendrimers as solubility enhancers of Silybin

References

• Albertazzi L, Gherardini L, Brondi M, Sato SS, Bifone A, Pizzorusso T, Ratto GM, Bardi G. 2013. In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharmaceutics. 10:249–260.
   PubMed Web of Science ®Google Scholar
• Ansari M. 2015. Investigations of polyethylene glycol mediated ternary molecular inclusion complexes of silymarin with beta cyclodextrins. J App Pharm Sci. 5:026–031.
   Google Scholar
• Astruc D, Boisselier E, Ornelas C. 2010. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem Rev. 110:1857–1959.
   PubMed Web of Science ®Google Scholar
• Barraza LF, Jiménez VA, Alderete JB. 2015. Effect of PEGylation on the structure and drug loading capacity of PAMAM‐G4 dendrimers: a molecular modeling approach on the complexation of 5‐fluorouracil with native and PEGylated PAMAM‐G4. Macromol Chem Phys. 216:1689–1701.
   Web of Science ®Google Scholar
• Barraza LF, Jimenez VA, Alderete JB. 2016. Methotrexate complexation with native and PEGylated PAMAM-G4: effect of the PEGylation degree on the drug loading capacity and release kinetics. Macromol Chem Phys. 217:605–613.
   Web of Science ®Google Scholar
• Barraza LF, Jimenez VA, Alderete JB. 2017. Association of methotrexate with native and PEGylated PAMAM-G4 dendrimers: effect of the PEGylation degree on the drug-loading capacity and preferential binding sites. J Phys Chem B. 121:4–12.
   PubMed Web of Science ®Google Scholar
• Cao X, Deng WW, Fu M, Zhu Y, Liu HF, Wang L, Zeng J, Wei YW, Xu XM, Yu JN. 2013. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs. Eur J Pharm Sci. 48:64–71.
   PubMed Web of Science ®Google Scholar
• Connors KA. 1987. Binding constants: the measurement of molecular complex stability. New York: Wiley-Interscience.
   Google Scholar
• Cheng YY, Zhao LB, Li YW, Xu TW. 2011. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev. 40:2673–2703.
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, Chowdhury P. 2010. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 67:217–223.
   PubMed Web of Science ®Google Scholar
• Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 57:2215–2237.
   PubMed Web of Science ®Google Scholar
• Esfand R, Tomalia DA. 2001. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 6:427–436.
   PubMed Web of Science ®Google Scholar
• Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. 2003. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 24:1121–1131.
   PubMed Web of Science ®Google Scholar
• Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 93:139–143.
   PubMed Web of Science ®Google Scholar
• Gazak R, Walterova D, Kren V. 2007. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem. 14:315–338.
   PubMed Web of Science ®Google Scholar
• Huang X, Wu ZH, Gao W, Chen Q, Yu B. 2011. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev Ind Pharm. 37:419–427.
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, Jain NK. 2010. Dendrimer toxicity: let's meet the challenge. Int J Pharm. 394:122–142.
   PubMed Web of Science ®Google Scholar
• Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. 2003. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm. 252:263–266.
   PubMed Web of Science ®Google Scholar
• Jiang Y-Y, Tang G-T, Zhang L-H, Kong S-Y, Zhu S-J, Pei Y-Y. 2010. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J Drug Target. 18:389–403.
   PubMed Web of Science ®Google Scholar
• Kellici TF, Ntountaniotis D, Leonis G, Chatziathanasiadou M, Chatzikonstantinou AV, Becker-Baldus J, Glaubitz C, Tzakos AG, Viras K, Chatzigeorgiou P, et al. 2015. Investigation of the Interactions of Silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods. Mol Pharm. 12:954–965.
   PubMed Web of Science ®Google Scholar
• Kojima C, Kono K, Maruyama K, Takagishi T. 2000. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chem. 11:910–917.
   PubMed Web of Science ®Google Scholar
• Kumar N, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P, Mathew G, Kutty NG, Udupa N, Rao CM. 2014. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol Rep. 66:788–798.
   PubMed Web of Science ®Google Scholar
• Lee H, Larson RG. 2011. Effects of PEGylation on the size and internal structure of dendrimers: self-penetration of long PEG chains into the dendrimer core. Macromolecules. 44:2291–2298.
   Web of Science ®Google Scholar
• Luong D, Kesharwani P, Deshmukh R, Mohd Amin MCI, Gupta U, Greish K, Iyer AK. 2016. PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. 43:14–29.
   PubMed Web of Science ®Google Scholar
• Ly TU, Tran NQ, Thi KDH, Phan KN, Truong HN, Nguyen CK. 2013. Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. J Biomed Nanotechnol. 9:213–220.
   PubMed Web of Science ®Google Scholar
• Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. 2000. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 65:133–148.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Yu H, Dong BX, Hadinoto K. 2016. A supersaturating delivery system of silibinin exhibiting high payload achieved by amorphous nano-complexation with chitosan. Eur J Pharm Sci. 89:163–171.
   PubMed Web of Science ®Google Scholar
• Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A. 2016. Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection. J Biomed Nanotechnol. 12:770–780.
   PubMed Web of Science ®Google Scholar
• Ryan SM, Mantovani G, Wang XX, Haddleton DM, Brayden DJ. 2008. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv. 5:371–383.
   PubMed Web of Science ®Google Scholar
• Saller R, Meier R, Brignoli R. 2001. The use of silymarin in the treatment of liver diseases. Drugs. 61:2035–2063.
   PubMed Web of Science ®Google Scholar
• Thakur S, Kesharwani P, Tekade RK, Jain NK. 2015. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer. 59:67–92.
   Web of Science ®Google Scholar
• Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. 1985. A new class of polymers: starburst–dendritic macromolecules. Polym J. 17:117–132.
   Google Scholar
• Tomalia DA, Naylor AM, Goddard WA. 1990. Starburst dendrimers: molecular‐level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl. 29:138–175.
   Web of Science ®Google Scholar
• Wang YC, Zhang L, Wang QW, Zhang DR. 2014. Recent advances in the nanotechnology-based drug delivery of silybin. J Biomed Nanotechnol. 10:543–558.
   PubMed Web of Science ®Google Scholar
• Wei W, Wei X, Jiangling W, Xiaohui S, Huibi X, Xiangliang Y. 2009. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology. 20:105103.
   Web of Science ®Google Scholar
• Wellington K, Jarvis B. 2001. Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs. 15:465–489.
   PubMed Web of Science ®Google Scholar
• Xie YC, Yi YN, Hu XW, Shangguan M, Wang LJ, Lu Y, Qi JP, Wu W. 2016. Synchronous microencapsulation of multiple components in silymarin into PLGA nanoparticles by an emulsification/solvent evaporation method. Pharm Dev Technol. 21:672–679.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhao YP, Zhang YT, Dang BL, Liu Y, Feng NP. 2015. Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo. Int J Nanomed. 10:6633–6644.
   PubMed Web of Science ®Google Scholar
• Yang H, Lopina ST. 2003. Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed. 14:1043–1056.
   PubMed Web of Science ®Google Scholar
• Yang L, da Rocha SRP. 2014. PEGylated, NH2-terminated PAMAM dendrimers: a microscopic view from atomistic computer simulations. Mol Pharm. 11:1459–1470.
   PubMedGoogle Scholar
• Zheng DD, Wang YC, Zhang DR, Liu ZP, Duan CX, Jia LJ, Wang FH, Liu Y, Liu GP, Hao LL, et al. 2011. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett. 307:158–164.
   PubMed Web of Science ®Google Scholar
• Zhou XD, Chen ZP. 2015. Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Arch Pharm Res. 38:2193–2200.
   PubMed Web of Science ®Google Scholar
• Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y. 2010. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials. 31:1360–1371.
   PubMed Web of Science ®Google Scholar